Clinical Trial

A Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated September 26, 2024 (before its estimated June 24, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a first-in-human (FIH) study to evaluate the safety and preliminary efficacy of experimental drug HDM2005 in patients with relapsed/refractory B-cell lymphoma and advanced solid tumors.
Trial Details
NCT Number NCT06615193
Lead Sponsor Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Conditions Advanced Solid Tumors, Refractory Lymphoma, Relapsed Hematologic Malignancy
Enrollment 111 participants
Start Date 2024-08-12
Primary Completion 2026-06-24 (estimated)
Study Completion 2028-02-01 (estimated)
Updated on ClinicalTrials.gov 2024-09-26